Crizotinib in the treatment of non-small-cell lung cancer Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines

abstract

  • Crizotinib represents the newest example of a focused strategy for drug development in lung cancer, based on identification and targeted inhibition of critical tumor-specific driver mutations. Crizotinib has demonstrated efficacy against ALK-rearranged NSCLC, and has potential for broader application in select subsets of lung cancer.

publication date

  • June 2012

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1517/14656566.2012.688029

PubMed ID

  • 22594847

Additional Document Info

start page

  • 1195

end page

  • 201

volume

  • 13

number

  • 8